The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function




The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function

• The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It
• Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level
• How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function
• Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational health, has published a comprehensive educational resource exploring the role of the endothelial glycocalyx (EGX) in everyday circulation. The article, Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx, provides an accessible overview of the science behind a vascular structure most people have never heard of.

Dr. Joel Kahn, MD, integrative cardiologist, founder of the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and frequent educator for Calroy, explains: “The glycocalyx is a gel-like lining inside every blood vessel. When it’s intact, blood flows the way it should. When it thins, the body feels it — even before standard tests pick anything up.”

KEY FACTS

• The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel, helping regulate vascular function throughout the body, including at the microvascular level.
• Research published in the National Library of Medicine has identified vascular elasticity as a marker of endothelial function (PubMed: 28356037).
• The EGX plays a functional role in supporting the movement of nutrients and oxygen from blood vessels into surrounding tissue.
• Most routine cardiovascular screenings focus on large arteries and do not assess endothelial glycocalyx integrity or microvascular function.
• Calroy Health Sciences utilizes patented microfluidic chip technology to simulate vascular conditions in a lab-on-a-chip environment to study endothelial glycocalyx behavior.
• MonitumRS®, a proprietary extract of Rhamnan sulfate from Monostroma nitidum, is scientifically shown to protect and restore the endothelial glycocalyx.*†

The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It

The endothelial glycocalyx is one of the most important structures in the vascular system — and one of the least discussed. This delicate, micro-thin lining coats the interior of every blood vessel in the body, from the largest arteries to the smallest capillaries. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation.*

When the glycocalyx is intact, blood flow at the microvascular level proceeds efficiently. Maintaining glycocalyx integrity supports efficient nutrient delivery and vascular responsiveness at the capillary level. The Calroy Health Sciences education center provides a detailed introduction to how the glycocalyx functions within the broader circulatory system.

Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level

Most cardiovascular assessments focus on large-vessel metrics — arterial imaging and standard panels that evaluate the body’s primary supply routes. These tools are valuable, but they do not evaluate what is happening at the microvascular level. The glycocalyx exists in the smallest blood vessels — the capillaries — where nutrient exchange actually occurs. This means a person can receive clear results from standard vascular screenings while their microcirculation tells a different story.

A peer-reviewed study available through the National Library of Medicine found that vascular elasticity markers can serve as early indicators of endothelial function, suggesting that tools beyond standard panels may be needed to understand full circulatory health. Calroy’s proprietary microfluidic chip technology was developed to help address this gap by simulating vascular conditions in a controlled lab-on-a-chip environment.

How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function

Calroy Health Sciences has built research around a simple question: can the glycocalyx be supported through targeted nutritional science? The company’s approach combines published peer-reviewed research with proprietary technology. Its research library includes studies on Rhamnan sulfate, nitric oxide pathways, and cartilage support.

Dr. Kahn notes: “What makes the glycocalyx conversation so important is that it connects how people feel every day — their energy, their clarity, their recovery — to a structure that science can study and support.”

The company’s Science and Medical Advisory Board includes physicians, researchers, and practitioners who guide product development and ensure claims are rooted in published science.

Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

The glycocalyx is a structure to support — and lifestyle factors including diet, movement, hydration, and targeted supplementation all play a role in maintaining glycocalyx integrity. Calroy’s educational approach emphasizes that an antioxidant-dense diet, regular movement, healthy sleep routines, and mindfulness all contribute to overall wellness and vascular well-being. The company’s flagship product, Arterosil HP® with MonitumRS®, supports vascular integrity and healthy circulation.*

MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† Additional resources on EGX science are available at Calroy’s introduction to the endothelial glycocalyx and through practitioner-focused research on the EGX.

FREQUENTLY ASKED QUESTIONS

Why do I still feel tired even though my blood work is normal? 

Standard panels assess large-vessel markers but do not always evaluate microvascular function or glycocalyx integrity. Reduced blood flow at the capillary level — where oxygen and nutrient exchange actually happens — may affect energy and recovery even when routine screenings come back with clear results.

What is microcirculation and why does it matter? 

Microcirculation is the movement of blood through your smallest vessels — the capillaries. It’s where your body actually delivers oxygen and nutrients to tissue. Just like  large-artery circulation, microcirculation is also influenced by a structure called the endothelial glycocalyx, which most people have never heard of. A detailed overview is available at calroy.com/education/microcirculation-and-blood-flow.

What does the lining of your blood vessels actually do? 

The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the interior of every blood vessel. It acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production. When the glycocalyx is compromised, circulation is affected and every organ feels the impact.

Are there tests that measure how well blood flows in small blood vessels? 

Most standard cardiovascular screenings focus on large arteries and many don’t assess microvascular function. Emerging research, including a peer-reviewed study on vascular elasticity markers (PubMed: 28356037), suggests that new tools may be needed to evaluate what’s happening at the capillary level.

Can what you eat affect your blood vessels?

Yes. Lifestyle factors including diet, hydration, movement, and healthy sleep routines can influence the integrity of the vascular system and likely the endothelial glycocalyx — the structure that lines every blood vessel and supports microcirculation. An antioxidant-rich diet and regular movement support cardiovascular and overall health.*

What supplements actually help with circulation? 

The endothelial glycocalyx is the micro-thin lining inside every blood vessel where blood flow regulation begins at the capillary level. Arterosil HP® with MonitumRS® supports vascular integrity and healthy circulation.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† 

What is the difference between arteries and capillaries? 

Arteries carry blood away from the heart through large vessels. Capillaries are the smallest vessels where the actual exchange of oxygen, nutrients, and waste occurs at the tissue level. The endothelial glycocalyx plays a key role in regulating the entire vascular system, including large arteries and tiny capillaries.

PUBLISHED RESEARCH & RESOURCES

• Research on the Endothelial Glycocalyx — Practitioner Resources
• Research on Rhamnan Sulfate from Monostroma Nitidum — Practitioner Resources
• Research on Nitric Oxide and the Vascular System — Practitioner Resources
• Markers of Vascular Elasticity and Endothelial Integrity — PubMed
• Calroy’s Published Research — Calroy Health Sciences
• Calroy’s Patents — Calroy Health Sciences
• Science and Medical Advisory Board — Calroy Health Sciences
• Quarterly Anchor Article — Calroy Health Sciences

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As demonstrated in an independent third-party laboratory in vitro study.Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) —

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

OKYO Pharma Announces Chairman and Founder Acquires Shares




OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function




The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function

• The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It
• Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level
• How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function
• Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) — Calroy Health Sciences, a science-driven dietary supplement company focused on foundational health, has published a comprehensive educational resource exploring the role of the endothelial glycocalyx (EGX) in everyday circulation. The article, Microcirculation and Blood Flow: The Missing Link Between How You Feel Every Day and the Endothelial Glycocalyx, provides an accessible overview of the science behind a vascular structure most people have never heard of.

Dr. Joel Kahn, MD, integrative cardiologist, founder of the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan, and frequent educator for Calroy, explains: “The glycocalyx is a gel-like lining inside every blood vessel. When it’s intact, blood flows the way it should. When it thins, the body feels it — even before standard tests pick anything up.”

KEY FACTS

• The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the inside of every blood vessel, helping regulate vascular function throughout the body, including at the microvascular level.
• Research published in the National Library of Medicine has identified vascular elasticity as a marker of endothelial function (PubMed: 28356037).
• The EGX plays a functional role in supporting the movement of nutrients and oxygen from blood vessels into surrounding tissue.
• Most routine cardiovascular screenings focus on large arteries and do not assess endothelial glycocalyx integrity or microvascular function.
• Calroy Health Sciences utilizes patented microfluidic chip technology to simulate vascular conditions in a lab-on-a-chip environment to study endothelial glycocalyx behavior.
• MonitumRS®, a proprietary extract of Rhamnan sulfate from Monostroma nitidum, is scientifically shown to protect and restore the endothelial glycocalyx.*†

The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It

The endothelial glycocalyx is one of the most important structures in the vascular system — and one of the least discussed. This delicate, micro-thin lining coats the interior of every blood vessel in the body, from the largest arteries to the smallest capillaries. Only recently discovered and often overlooked, it is foundational to vascular health and total-body vitality. The EGX acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production — the molecule that helps blood vessels relax and support healthy circulation.*

When the glycocalyx is intact, blood flow at the microvascular level proceeds efficiently. Maintaining glycocalyx integrity supports efficient nutrient delivery and vascular responsiveness at the capillary level. The Calroy Health Sciences education center provides a detailed introduction to how the glycocalyx functions within the broader circulatory system.

Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the Microvascular Level

Most cardiovascular assessments focus on large-vessel metrics — arterial imaging and standard panels that evaluate the body’s primary supply routes. These tools are valuable, but they do not evaluate what is happening at the microvascular level. The glycocalyx exists in the smallest blood vessels — the capillaries — where nutrient exchange actually occurs. This means a person can receive clear results from standard vascular screenings while their microcirculation tells a different story.

A peer-reviewed study available through the National Library of Medicine found that vascular elasticity markers can serve as early indicators of endothelial function, suggesting that tools beyond standard panels may be needed to understand full circulatory health. Calroy’s proprietary microfluidic chip technology was developed to help address this gap by simulating vascular conditions in a controlled lab-on-a-chip environment.

How Published Research and Patented Lab-on-a-Chip Technology Are Advancing What We Know About Glycocalyx Function

Calroy Health Sciences has built research around a simple question: can the glycocalyx be supported through targeted nutritional science? The company’s approach combines published peer-reviewed research with proprietary technology. Its research library includes studies on Rhamnan sulfate, nitric oxide pathways, and cartilage support.

Dr. Kahn notes: “What makes the glycocalyx conversation so important is that it connects how people feel every day — their energy, their clarity, their recovery — to a structure that science can study and support.”

The company’s Science and Medical Advisory Board includes physicians, researchers, and practitioners who guide product development and ensure claims are rooted in published science.

Why Lifestyle Factors Like Diet, Movement, and Targeted Supplementation May Help Maintain Glycocalyx Integrity

The glycocalyx is a structure to support — and lifestyle factors including diet, movement, hydration, and targeted supplementation all play a role in maintaining glycocalyx integrity. Calroy’s educational approach emphasizes that an antioxidant-dense diet, regular movement, healthy sleep routines, and mindfulness all contribute to overall wellness and vascular well-being. The company’s flagship product, Arterosil HP® with MonitumRS®, supports vascular integrity and healthy circulation.*

MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† Additional resources on EGX science are available at Calroy’s introduction to the endothelial glycocalyx and through practitioner-focused research on the EGX.

FREQUENTLY ASKED QUESTIONS

Why do I still feel tired even though my blood work is normal? 

Standard panels assess large-vessel markers but do not always evaluate microvascular function or glycocalyx integrity. Reduced blood flow at the capillary level — where oxygen and nutrient exchange actually happens — may affect energy and recovery even when routine screenings come back with clear results.

What is microcirculation and why does it matter? 

Microcirculation is the movement of blood through your smallest vessels — the capillaries. It’s where your body actually delivers oxygen and nutrients to tissue. Just like  large-artery circulation, microcirculation is also influenced by a structure called the endothelial glycocalyx, which most people have never heard of. A detailed overview is available at calroy.com/education/microcirculation-and-blood-flow.

What does the lining of your blood vessels actually do? 

The endothelial glycocalyx is a delicate, micro-thin, gel-like lining that coats the interior of every blood vessel. It acts as a semi-permeable barrier, facilitates smooth blood flow, and houses the enzymes involved in nitric oxide production. When the glycocalyx is compromised, circulation is affected and every organ feels the impact.

Are there tests that measure how well blood flows in small blood vessels? 

Most standard cardiovascular screenings focus on large arteries and many don’t assess microvascular function. Emerging research, including a peer-reviewed study on vascular elasticity markers (PubMed: 28356037), suggests that new tools may be needed to evaluate what’s happening at the capillary level.

Can what you eat affect your blood vessels?

Yes. Lifestyle factors including diet, hydration, movement, and healthy sleep routines can influence the integrity of the vascular system and likely the endothelial glycocalyx — the structure that lines every blood vessel and supports microcirculation. An antioxidant-rich diet and regular movement support cardiovascular and overall health.*

What supplements actually help with circulation? 

The endothelial glycocalyx is the micro-thin lining inside every blood vessel where blood flow regulation begins at the capillary level. Arterosil HP® with MonitumRS® supports vascular integrity and healthy circulation.* MonitumRS is scientifically shown to protect and restore the endothelial glycocalyx.*† 

What is the difference between arteries and capillaries? 

Arteries carry blood away from the heart through large vessels. Capillaries are the smallest vessels where the actual exchange of oxygen, nutrients, and waste occurs at the tissue level. The endothelial glycocalyx plays a key role in regulating the entire vascular system, including large arteries and tiny capillaries.

PUBLISHED RESEARCH & RESOURCES

• Research on the Endothelial Glycocalyx — Practitioner Resources
• Research on Rhamnan Sulfate from Monostroma Nitidum — Practitioner Resources
• Research on Nitric Oxide and the Vascular System — Practitioner Resources
• Markers of Vascular Elasticity and Endothelial Integrity — PubMed
• Calroy’s Published Research — Calroy Health Sciences
• Calroy’s Patents — Calroy Health Sciences
• Science and Medical Advisory Board — Calroy Health Sciences
• Quarterly Anchor Article — Calroy Health Sciences

About Calroy Health Sciences

Calroy Health Sciences is a science-driven dietary supplement company dedicated to supporting foundational health. Co-founded by CEO Ed Hoyt and Chief Scientific Officer Chen Chen, PhD, Calroy brings more than three decades of combined experience in the dietary supplement industry. The company’s breakthrough products — Arterosil HP® with MonitumRS®, Vascanox HP® with Noxa24®, and Cartigenix HP® with RestorCel™ — are developed through a research-first approach that includes studying the finished formulated product, not just individual ingredients. 

Calroy’s research has been published in peer-reviewed journals and is conducted in partnership with major academic institutions, leading clinicians and researchers. The company also holds patents on its products and its microfluidic chip testing technology. For more information, visit calroy.com.

SME Available for Commentary: Joel Kahn, MD — Integrative Cardiologist, Kahn Center for Cardiac Longevity

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

†As demonstrated in an independent third-party laboratory in vitro study.Scottsdale, AZ, March 19, 2026 (GLOBE NEWSWIRE) —

CONTACT: Sarah Evans
Partner, Head of PR, Zen Media
sarah@zenmedia.com

OKYO Pharma Announces Chairman and Founder Acquires Shares




OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company’s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

Inquiries:

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss




Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

• Wegovy^® HD demonstrated a mean weight loss of 20.7%¹, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial
• First US FDA approval of a GLP-1 treatment under the Commissioner’s National Priority Voucher pilot programme, for products addressing critical US national health priorities
• Wegovy^® HD complements Wegovy^® 2.4 mg, which is already approved in the US for weight management and cardiovascular risk reduction
• Novo Nordisk expects to launch Wegovy^® HD in the US in April 2026

Bagsværd, Denmark, 19 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy^® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term. The FDA awarded a Commissioner’s National Priority Voucher for Wegovy^® HD, accelerating its review and underscoring its potential to address critical patient needs and national health priorities in the US.

The accelerated approval is based on results from the STEP UP trial programme. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%¹ mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss. In the STEP UP type 2 diabetes (T2D) trial, in participants with obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1%¹. In both trials, the well-known safety and tolerability profile of semaglutide was reaffirmed with semaglutide 7.2 mg, which was comparable to previous trials with semaglutide for weight management.

“Since its launch in 2021, Wegovy^® has transformed the lives of many people living with obesity and helped them achieve meaningful weight loss and important cardiometabolic benefits, including an unprecedented reduction in cardiovascular risk,” said Mike Doustdar, president and CEO of Novo Nordisk. “Earlier this year, we launched the Wegovy^® pill, and with the accelerated approval of Wegovy^® HD, we are introducing a new offering for our injectable semaglutide that provides even greater weight loss of approximately 21%. At Novo Nordisk, our goal is to provide innovative therapies that support healthier lives for people living with obesity, and we look forward to launching Wegovy^® HD to help even more people reach their weight and health goals.”

Novo Nordisk expects to launch Wegovy^® HD in a single-dose pen in the US in April 2026.

Wegovy^® 7.2 mg is already approved for adults with obesity in the EU and the UK. Novo Nordisk expects regulatory decisions in the EU and the UK on semaglutide 7.2 mg in a single-dose pen in the second half of 2026.

About the STEP UP trials
The STEP UP and STEP UP T2D phase 3 trials investigated the efficacy and safety of injectable semaglutide 7.2 mg in people with obesity with or without type 2 diabetes.

The 72-week STEP UP trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included approximately 1,400 adults with obesity. The 72-week STEP UP T2D trial evaluated the efficacy and safety of injectable semaglutide 7.2 mg compared to placebo in approximately 500 adults with obesity and type 2 diabetes.

^* Treatment effect if all people adhered to treatment, ^** Treatment effect regardless of treatment adherence

About Wegovy^®
Wegovy^® is approved as once-daily Wegovy^® pill (semaglutide tablet 25 mg) and once-weekly Wegovy^® injections (semaglutide 1.7 mg, 2.4 mg and 7.2 mg) by the FDA.

Wegovy^® is approved as a once-weekly injection by the EMA and by other regulatory authorities worldwide. The Wegovy^® pill is currently pending marketing approval from the EMA and other regulatory authorities.

Wegovy^® is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight and in the presence of at least one weight-related comorbid condition, and approved by the FDA to reduce the risk of major adverse cardiovascular events, such as death, heart attack or stroke in adults with known heart disease and either obesity or overweight. Furthermore, Wegovy^® injection is indicated to reduce excess body weight and maintain long-term weight reduction in paediatric patients aged 12 years and older. It is approved by the FDA for the treatment of MASH in adults with moderate to advanced liver scarring (fibrosis), but not in those with cirrhosis of the liver.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Publication of inside information pursuant to Market Abuse Regulation, Article 17.

Contacts for further information

Company announcement No 19 / 2026

¹ Based on the efficacy estimand: treatment effect if all people adhered to treatment

Attachment

• CA260319-Wegovy-HD-FDA-approval

Notice to convene Evaxion’s Annual General Meeting




Notice to convene Evaxion’s Annual General Meeting

COPENHAGEN, Denmark, March 19, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.

The meeting will be held at the company’s offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.

The agenda and proposals can be found on Evaxion’s website, along with other materials:
www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform




Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform

ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development.

The Glasgow, UK, site is well known throughout the industry for its more than 25 years of experience with formulation, lyophilization development and sterile fill-finish capabilities, including ADCs and other highly potent products. The current expansion is expected to be completed by early 2027. The investment will add an Annex 1 compliant isolator-based vial filling line and lyophilizer. Once complete, Glasgow will be able to fill batches up to 20,000 vials and will be well‑positioned to support future small‑scale commercial fills.

“This expansion in Glasgow comes as Curia is nearing completion of our significant expansion in our commercial drug product facility in Albuquerque, NM,” said Ron Aungst, VP, Drug Product Business Unit Operations. “Curia has already secured crucial equipment with long lead times to help the Glasgow expansion project stay on track, and we do not anticipate any disruption to current operations during the expansion.”

Curia’s clinical drug substance development capabilities have also been enhanced with improvements to the company’s cell line development (CLD) platform. The CLD offering at Curia’s Hopkinton, MA facility has been enhanced to incorporate IP-free semi-targeted integration technology that results in 6-fold higher titers compared to random integration technology. Curia’s stable platform, CHO-GSN®, was derived from the same parental cell line as its transient platform, TunaCHO®, allowing partners to efficiently scale-up from discovery to GMP.

“Our biologics division has always had end-to-end capabilities, and we are excited to offer a cell line that makes it more cost-efficient and faster to advance partners through early-stage clinical manufacturing,” said Jamie Grabowski, President, Research & Development. “With biotech-friendly licensing terms, reengineered cell line will be a critical component of successfully guiding partners on their path to commercialization.”

About Curia
Curia is a contract research, development and manufacturing organization (CDMO) with over 30 years of experience, an integrated network of 20+ global sites and 3,100 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our offerings in small molecule, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026




Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation 

Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS-driven tumors

Pelareorep’s ability to engage the innate and adaptive immune system results in doubling or nearly tripling response rates in breast and gastrointestinal cancers

SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced two abstracts across distinct tumor types were accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting 2026, at the San Diego Convention Center from April 17-22, 2026. Pelareorep is an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways via double‑stranded RNA signaling, driving interferon production, dendritic cell activation, and cytotoxic T‑cell priming.

“These new translational findings strengthen our understanding of pelareorep as a systemic immune‑priming agent that reshapes the tumor microenvironment,” said Jared Kelly, Chief Executive Officer of Oncolytics. “The coordinated immune activation and tertiary lymphoid structure formation we are observing support pelareorep as a foundational backbone for combination therapy across multiple tumor types, including RAS-driven cancers. RAS mutations are especially prevalent in deadly cancers, including roughly 95% of pancreatic cancers and 45% of colorectal cancers. As we advance registrational programs in gastrointestinal cancers, we believe pelareorep will enhance immunotherapy activity and potentially help patients who did not respond initially.”

Biomarker data from cohort 1 of the Phase 1/2 GOBLET trial in advanced pancreatic cancer suggest pelareorep plus atezolizumab and gemcitabine/nab-paclitaxel can shift tumors toward a more immune-active state. Patients with an immune activation signature after four weeks were more likely to achieve durable clinical benefit, supporting a potential biomarker. Pancreatic cancer continues to pose a significant unmet clinical need, with approximately 510,000 new cases reported globally each year.¹

Additionally, new first-of-its-kind data from AWARE-1 show pelareorep can drive coordinated anti-tumor immune responses, including tertiary lymphoid structure (“TLS”) formation, helping make immunologically cold tumors more susceptible to immunotherapy. This could include patients who have failed checkpoint inhibitors, representing a significant portion of the patient population and a meaningful unmet need in oncology.

Pelareorep has also been shown to stimulate RAS-specific T-cell clones in gastrointestinal cancers, which may enhance its ability to target RAS-mutated tumor cells. The Company will present more data on this topic at an upcoming scientific meeting.

Together, the data support pelareorep as a novel immune‑priming strategy capable of enhancing the activity of multiple therapeutic classes, including checkpoint inhibitors, targeted therapies, chemotherapy, and emerging immuno‑oncology modalities.

Abstract: Pelareorep combined with atezolizumab and chemotherapy shows immune conversion activity in advanced pancreatic cancer: Biomarker results of cohort 1 of the GOBLET trial

New biomarker data from cohort 1 of the Phase 1/2 GOBLET study demonstrated that pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel led to meaningful immune activation in patients with metastatic pancreatic ductal adenocarcinoma (“mPDAC”).

An exploratory analysis integrating routine serum markers, a 172-protein circulating panel, selected T-cell receptor sequencing, and clinical outcomes found early on-treatment changes showed increases in adaptive immune and cytotoxicity-associated proteins, including interferon signaling and CD8+/NK-related markers, alongside decreases in tumor/stroma-associated proteins. A 14-protein signature linked to oncolytic activity stratified patients at Week 4 into ‘hot’ vs. ‘cold’ immune phenotypes relative to baseline. Patients demonstrating immune activation signatures experienced longer median progression-free survival (7.5 months) compared with patients who did not exhibit similar immune responses (5.6 months).

As previously reported, the combination of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel demonstrated a 62% objective response rate in first-line mPDAC patients, more than double the response rates historically observed with chemotherapy alone.

Abstract: Imaging mass cytometry of pelareorep treated early breast cancer samples reveals developing tertiary lymphoid structures

AWARE-1 is a window-of-opportunity study evaluating the effects of pelareorep in early-stage breast cancer. In biopsies from Cohort 2 (n=8), cellular neighborhood analysis identified immune-cell clusters, including cytotoxic T cells, dendritic cells, T helper cells, activated T helper cells, B cells, differentiated B cells, and M2 macrophages. Interactions between these cells developed into TLS in select patients. TLS function as localized immune hubs that facilitate antigen presentation, T‑cell activation, and sustained anti‑tumor immune responses. Published studies link TLS formation with improved responses to immunotherapy.

These findings support pelareorep’s potential to expand cytotoxic T cells, activate dendritic cells, and promote TLS formation, helping to convert immunologically ‘cold’ tumors into immune-responsive ‘hot’ tumors.

About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH. The co-primary endpoints of the study are objective response rate and/or disease control rate and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups:

1. Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1^st line advanced/metastatic pancreatic cancer patients;
2. Pelareorep in combination with atezolizumab in 1^st line MSI (microsatellite instability)-high metastatic colorectal cancer patients;
3. Pelareorep in combination with atezolizumab and TAS-102 in 3^rd line metastatic colorectal cancer patients
4. Pelareorep in combination with atezolizumab in 2^nd line advanced and unresectable anal cancer patients; and
5. Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.

About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.

About AWARE-1
AWARE-1 was an open-label window-of-opportunity study in early-stage breast cancer. The study combined pelareorep, without or with atezolizumab, and standard of care therapy according to breast cancer subtype. Tumor tissue was collected from patients as part of their initial breast cancer diagnosis, again on day three following initial treatment, and finally at three weeks following treatment, on the day their tumor is surgically resected. Key objectives of the study were to confirm that pelareorep is acting as a novel immunotherapy, to evaluate potential synergy between pelareorep and checkpoint blockade, and to collect biomarker data. The primary endpoint of the translational study was overall CelTIL score (a measurement of cellularity and tumor-infiltrating lymphocytes that is associated with favorable clinical outcomes). Secondary endpoints for the study included safety and tumor and blood-based biomarkers. The combination of pelareorep, letrozole, and atezolizumab resulted in 60% of patients experiencing 30% or greater increases in their CelTIL score.

Reference

1. Leiphrakpam PD, Chowdhury S, Zhang M, et al. Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes. J Gastrointest Cancer. 2025 Feb 24;56(1):71.

About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.

Tecentriq^® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the timing of the AACR Annual Meeting 2026; expectations as to the content and potential opportunities associated with the findings from the various studies expected to be presented via abstracts in the future; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; anticipated timelines and objectives for future meetings with regulatory bodies, including the FDA; and its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers as well as breast cancer. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca

Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025




Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025

NESS ZIONA, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains Sol-Gel’s audited annual financial statements for 2025, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at https://ir.sol-gel.com/financials/sec-filings. The Company will deliver a hard copy of its 2025 annual report on Form 20-F, including its complete audited financial statements, free of charge to its shareholders, upon request to Eyal Ben-Or, Chief Financial Officer, at Eyal.Ben-Or@sol-gel.com.

Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.

To learn more about Sol-Gel, visit www.sol-gel.com

Sol-Gel Investor Relations:
Eyal Ben-Or
Chief Financial Officer
ir@sol-gel.com

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder




Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

This positive progress follows the Company’s recent announcement on March 11, 2026, regarding the advancement of participant enrollment for the third cohort at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. Patients at the prestigious U.S. institutions – Yale University and Johns Hopkins University – continue to progress successfully through their treatment protocol, demonstrating continued safety and tolerability with no serious adverse events reported to date.

The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The successful ongoing treatment at these leading U.S. medical centers reflects strong momentum and confidence in CMND-100 as a potential breakthrough therapy for AUD.

“Building on the encouraging recruitment momentum and positive topline results from prior cohorts, we are pleased with the successful continuation of treatment in our U.S. clinical sites,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.